LTR Pharma Ltd
ASX:LTP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.25
2.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
LTR Pharma Ltd
Net Issuance of Common Stock
LTR Pharma Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
LTR Pharma Ltd
ASX:LTP
|
Net Issuance of Common Stock
AU$7m
|
CAGR 3-Years
308%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Issuance of Common Stock
-AU$10.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Issuance of Common Stock
AU$4.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-17%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Issuance of Common Stock
AU$100.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
179%
|
CAGR 10-Years
39%
|
|
|
Probiotec Ltd
ASX:PBP
|
Net Issuance of Common Stock
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Net Issuance of Common Stock
AU$14.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
LTR Pharma Ltd
Glance View
LTR Pharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.
See Also
What is LTR Pharma Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
7m
AUD
Based on the financial report for Jun 30, 2024, LTR Pharma Ltd's Net Issuance of Common Stock amounts to 7m AUD.
What is LTR Pharma Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
308%
Over the last year, the Net Issuance of Common Stock growth was 384%. The average annual Net Issuance of Common Stock growth rates for LTR Pharma Ltd have been 308% over the past three years .
You don't have any saved screeners yet